Feed / BBIO

BridgeBio Pharma, Inc.

BBIO

Healthcare · 81.47 -1.8% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

BridgeBio Pharma, Inc.'s move is being confirmed by its market group.

BBIO accounts for 14.3% of the group's measured movement across 6.0 effective names. raw member direction is mixed; 6 of 8 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#3 of 8 by movement share
Group movement share14.3%Absolute path energy—not portfolio weight
Relative path-1.72%aligned
Effective breadth6.0 / 8broad
Relative alignment6/8downside path · 1 counter-moving
Capital-flow agreement15%not yet clean
SEQUENCE READ

SMMT, ROIV, IBRX moved materially before BBIO. BBIO crossed its material path threshold at 11:10 ET, 5 minutes after the first measured mover. ARWR, CGON, BEAM followed.

EVIDENCE COVERAGE

5 of 8 members in Gene Editing Therapies are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 6 of 8 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as RLYB begins moving with the group.

Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.

Watch this read

Who this business touches

The relationships behind BBIO

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

GSGoldman Sachs Group, Inc. (The)partnerMay 7, 2026 ▾

“We also concurrently entered into an Equity Distribution Agreement (the “ATM Agreement”) with Goldman Sachs & Co.”

OWLBlue Owl Capital Inc.partnerAug 5, 2025 ▾

“the guarantors, which was amended on February 12, 2024 (the “Financing Agreement”) and June 20, 2024 (the Financing Agreement, as amended by the Second Amendment, the “Amended Financing Agreement”), with the lenders party thereto (the “Lenders”) and Blue Owl…”

Depended on by

KRYSKrystal Biotech, Inc. Common StockpartnerFeb 17, 2026 ▾

“We are also aware of a recombinant-protein-based approach being developed by BridgeBio Pharma, Inc.’s affiliate company, Phoenix Tissue Repair.”

Filing peers

RLYBINMDNLI

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 8 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

BBIO is currently a Participant in the organic co-movement group Gene Editing Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.